CURRICULUM VITAE

Full Name:	**Brady**	**Jennifer**	
	Last Name	First Name	Middle Initial

Professional Mailing Address: (Include institution name.)

IMIC research
18320 Franjo Rd
Palmetto Bay FL 33157

Telephone: 786-310-7477/ fax 305-252-2199, email: jennifer@aktamedika.com

Academic Qualifications (most current date first)

Degree/Certification	Date (YYYY)	Institution, Country
GCP	2017	CITI, Miami FL USA
Human Subjects Research	2012	CITI, Miami FL USA
Medical assistant	1996	National Institute of Technology, Miami FL USA South Dade Senior High, FL, USA
GED	1990	

Current and Previous 4 Relevant Positions Including Academic Appointments (most current date first):

Start and End Dates	Title	Institution or Company, State/Province/Country
2016- ongoing	Research Coordinator	IMIC, Inc., Miami FL USA
2014-2016	Research Coordinator	Homestead Medical Research, Inc.
2012-2014	Research Coordinator	IMIC, Inc Research clinic, Miami Beach FL USA
2006-2009	Patient Coordinator	IMIC, Inc., Miami FL USA
2000-2006	Medical Assistant	HealthRight Clinic, Doral FL USA
Experiences:	EDC – Medidata, Oc-RDC, Inform, Eclinical IWRS – Clinphone, Mytrials, Endpoint, Bracket ePro – EPX, CRF	

Brief Summary of Relevant Clinical Research Experience in the last 5 years:

Participation in 29 Clinical studies as CTC
in trials phase 2, 3 and 4 in cardiology –hypercholesterolemy, pulmonology – COPD and Asthma; endocrinology-diabetes type 2; Pain management; constipation, liver cirrhosis, ulcerative colitis, Crohn's disease.

Detailed description of participation in trials in the past 5 years:

2017-Protocol No. GS-US-384-1944: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH) as SC

2017-IDN-6556-17: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects with Decompensated Non-Alcoholic Steatohepatitis (NASH) Cirrhosis as SC

2016 - A Phase 3 Multi-Center, Randomized, Double- Blinded, Vehicle-Controlled, Parallel Group Study Comparing the Efficacy, Tolerability and Safety of Once Daily SB204 and Vehicle Gel in the Treatment of Acne Vulgaris as SC

2016 - IDN-6556-14: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects with Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension as SC

2016-E2609-G000-302: A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects with Early Alzheimer's Disease as SC

2016-E5501-G000-310: A Randomized, Global, Double-blind, Placebo-controlled, Parallel-

group Study to Evaluate the Efficacy and Safety of Once-daily Oral Avatrombopag for the Treatment of Adults with Thrombocytopenia Associated with Liver Disease Prior to an Elective Procedure as SC

2016-A Phase III Safety and Efficacy Study of ALZT-OP1 in Subjects with Evidence of Early Alzheimer's Disease as SC

2016- A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Outpatients with Early Alzheimer's Disease as SC

2016 - A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF GED-0507-34-LEVO (GED0507) FOR TREATMENT OF SUBJECTS WITH ACTIVE ULCERATIVE COLITIS, GED0507-UC-001 as SC

2016 - A Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of AVP-786 (deuterated [d6]-dextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for the treatment of agitation in patients with dementia of the Alzheimer's type as SC

2016 - A Phase 2, Randomized, Multicenter, Double-Blind, Active and Vehicle Controlled Parallel-group Study Evaluating the Efficacy, Safety, and Tolerability of Products S6G5T-3 and S6G5T-1 for the Treatment of Acne Vulgaris for 12 Weeks Sol-Gel Protocol Number: SGT-65-02 as SC

2016 - A Phase 2b Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects with Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti-Tumor Necrosis Factor-Alpha Therapy as SC

2016 - GA28951: AN OPEN-LABEL EXTENSION AND SAFETY MONITORING STUDY OF MODERATE TO SEVERE ULCERATIVE COLITIS PATIENTS PREVIOUSLY ENROLLED IN ETROLIZUMAB PHASE III STUDIES as SC

2015 - 000175 -A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Investigating the Efficacy and Safety of Mesalamine 2 g Extended Release Granules (Sachet) for Maintenance of Clinical and Endoscopic Remission in Ulcerative Colitis as SC

2015 - M13-740 -A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects with Moderately to Severely Active Crohn's Disease who have Inadequately Responded to or are Intolerant to Anti-TNF Therapy as SC

2015 - BLI400-303: An Open Label Study of Chronic Use of BLI400 Laxative in Constipated Adults as CTC

2015 - 000174 - A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Investigating the Efficacy and Safety of Mesalamine 4 g Extended Release Granules (Sachet) for the Induction of Clinical and Endoscopic Remission in Active, Mild to Moderate Ulcerative Colitis as SC

2013 - MKC-TI-134, A Phase 3, Multicenter, Open-label, Randomized Clinical Trial to Evaluate the Safety of Technosphere® Insulin Inhalation Powder in Type 1 or Type 2 Diabetic Subjects with Obstructive Pulmonary Disease (Asthma or Chronic Obstructive Pulmonary Disease) Over a 12-month Treatment Period with a 2-month Follow-up as CTC

2013 - A randomized double-blind placebo controlled parallel group study of the efficacy and safety of pregabalin (bid) in subjects with post-traumatic peripheral neuropathic pain as CTC

2013 -A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Naldemedine in the Treatment of Opioid-induced Constipation in Subjects with Non-malignant Chronic Pain Receiving Opioid Therapy as CTC

2013- Dey **Protocol 191-091**: Phase II - A 12-week Randomized, Multiple-Dose, Double-Blind, Placebo- Controlled, Parallel-Group Study to Evaluate Nebulized Fluticasone Propionate (FP) Dose Response in Adult Subjects with Partly Controlled and Uncontrolled Asthma as CTC.

2013 - DECLARE-TIMI 58 study (Dapagliflozin Effect on CardiovascuLAR Events) as CTC

2013 - Phase II - A 12-week Randomized, Multiple-Dose, Double-Blind, Placebo-Controlled, Parallel-Group Study to

Replicate Efficacy of Nebulized Fluticasone Propionate (FP) in Adult Subjects with Partly Controlled and Uncontrolled Asthma as CTC

2013 – Phase 4 - A 26 week, randomized, double-blind, parallel-group, active controlled, multicenter, multinational safety study evaluating the risk of serious asthma-related events during treatment with Symbicort®, a fixed combination of inhaled corticosteroid (ICS) (budesonide) and a long acting β2-agonist (LABA) (formoterol) as compared to treatment with ICS (budesonide) alone in adult and adolescent (≥12 years of age) patients with asthma as CTC

2013 – Phase 3 - ONU3705 A Randomized, Double-blind, Double-dummy, Placebo-controlled, Active-controlled, Parallel-group, Multicenter Trial of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess the Analgesic Efficacy (Compared to Placebo) and the Management of Opioid-induced Constipation (Compared to Oxycodone Controlled-release Tablets (OXY)) in Opioid-experienced Subjects with Controlled Moderate to Severe Chronic Low Back Pain and a History of Opioid-induced Constipation who Require Around-the clock Opioid Therapy as CTC

2013 - A Placebo-Controlled, Double-Blind, Parallel, Randomized, Clinical Dose-Confirming Study of Pulsed, Inhaled Nitric Oxide (iNO) in Subjects with World Health Organization (WHO) Group 3Pulmonary Hypertension (PH) Associated with Chronic Obstructive Pulmonary Disease (COPD) on Long-Term Oxygen Therapy (LTOT) as CTC

2013-Blacks and Exacerbations on Long Acting Beta Agonists (LABA) vs. Tiotropium (BELT) as CTC

2012-MB102073: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects with Type 2 Diabetes with inadequately controlled hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) as CTC

2012-MB102077: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects with Type 2 Diabetes with inadequately controlled hypertension treated with an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) and an additional Antihypertensive medication as CTC

Signature: 			**Signature Date:** May 1, 2017